Idarucizumab - Biologic Drug Details

Summary for idarucizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for idarucizumab

Recent Clinical Trials for idarucizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Boehringer Ingelheim
Boehringer Ingelheim	Phase 3
Boehringer Ingelheim	Phase 1

See all idarucizumab clinical trials

Pharmacology for idarucizumab

Established Pharmacologic Class	Humanized Monoclonal Antibody Fragment
Chemical Structure	Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for idarucizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for idarucizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	8,486,398	2031-01-20	DrugPatentWatch analysis and company disclosures
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	9,034,822	2033-06-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for idarucizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,501,773	2035-07-30	Patent claims search
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,590,182	2036-02-23	Patent claims search
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,703,800	2037-04-26	Patent claims search
Boehringer Ingelheim Pharmaceuticals, Inc.	PRAXBIND	idarucizumab	Injection	761025	10,954,549	2039-11-05	Patent claims search

International Patents for idarucizumab

Country	Patent Number	Estimated Expiration
France	17C1026
Denmark	2525812
Slovenia	2525812
Norway	2017034
South Africa	201202876
Mexico	2012008360

Supplementary Protection Certificates for idarucizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2017/030	Ireland		PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/15/1056/001 20151120
2017C/026	Belgium		PRODUCT NAME: PRAXBIND - IDARUCIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1056 20151124
CR 2017 00031	Denmark		PRODUCT NAME: IDARUCIZUMAB; REG. NO/DATE: EU/1/15/1056 20151124
283 14-2017	Slovakia		PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056 20151124
C201730027	Spain		PRODUCT NAME: IDARUCIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1056; DATE OF AUTHORISATION: 20151120; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1056; DATE OF FIRST AUTHORISATION IN EEA: 20151120
122017000046	Germany		PRODUCT NAME: LDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056 20151120

Market Dynamics and Financial Trajectory for Idarucizumab

Last updated: February 20, 2026

Idarucizumab (Praxbind) is a monoclonal antibody fragment designed as a specific reversal agent for dabigatran, a Direct Oral Anticoagulant (DOAC). Since its FDA approval in 2015, the drug has played a critical role in managing bleeding events associated with dabigatran therapy. Its market outlook is shaped by evolving anticoagulation treatment protocols, regulatory approvals, and clinical adoption trends.

Key Market Drivers

Clinical Necessity for Reversal Agents

Dabigatran's increasing use for stroke prevention in atrial fibrillation and venous thromboembolism (VTE) underscores demand for specific reversal agents. Idarucizumab fills this gap with rapid, targeted reversal, reducing bleeding complications and procedural risks.

Regulatory Approvals and Label Expansion

• Approved by FDA in 2015.
• Approved by EMA in 2015.
• The European label includes use in life-threatening or uncontrolled bleeding and as an emergency reversal before surgery.

Adoption Rates and Clinical Guidelines

Adoption is driven by clinical guidelines recommending idarucizumab in bleeding emergencies and urgent procedures. Physicians favor rapid reversal, especially in life-threatening cases.

Competitive Landscape

Unlike factor Xa inhibitors (apixaban, rivaroxaban), idarucizumab faces no direct competition; andexanet alfa is approved for factor Xa inhibitors. This positional advantage favors market growth but restricts the total reusable segment.

Market Size and Financial Performance

Revenue Generation

In 2021, global sales approximated $300 million, driven primarily by North America with approximately 70% market share. Sales are projected to grow at a Compound Annual Growth Rate (CAGR) of 10-12% over the next five years.

Sales Breakdown

Region	2021 Revenue	Market Share	Growth Rate (2022-2026, estimated)
North America	$210 million	70%	10%
Europe	$60 million	20%	12%
Rest of World	$30 million	10%	15%

Cost Structure

Manufacturing costs remain stable with high margins due to the antibody's biotech production process. The average gross margin exceeds 80%, with R&D expenses primarily allocated toward clinical validation and expanding label indications.

Market Trends and Future Outlook

Expansion Into New Indications

Ongoing trials explore idarucizumab’s efficacy for off-label uses, including extravascular bleeding and potentially other anticoagulant reversal needs.

Reimbursement Dynamics

High valuation by payers in high-income countries supports stable reimbursement pathways. In Europe, coverage varies; in the U.S., Medicare and private insurers provide broad coverage.

Impact of Competition and Innovation

• Andexanet alfa (Eliquis reversal) offers competition within the anticoagulant reversal market.
• Pending development of newer agents with longer half-lives or alternative delivery mechanisms could impact demand.

Regulatory and Policy Impacts

Increased emphasis on emergency preparedness and stroke prevention policies continues to advocate for availability of reversal agents. Regulatory pathways favor rapid approval for new indications, supporting sales expansion.

Financial Planning and Investment Considerations

Investment Risks

• Competitive pressure from emerging reversal agents can dampen growth.
• Limited patient population restricts overall market size.
• Pricing pressures and reimbursement policies influence margins.

Growth Opportunities

• Expansion into trauma and surgical settings.
• Broader reimbursement agreements in emerging markets.
• Partnership deals for distribution and clinical trials.

Summary

Idarucizumab remains a core reversal agent for dabigatran in high-income markets. Sales are expected to grow steadily due to increasing dabigatran prescriptions and clinical protocol adoption. Competitive dynamics are influenced by alternative reversal agents and evolving treatment guidelines. Long-term growth hinges on expanding indications, market penetration in emerging regions, and regulatory support.

Key Takeaways

• Idarucizumab's market value was approximately $300 million in 2021.
• North America generates approximately 70% of sales.
• Projected CAGR over five years is 10-12%.
• Competition from andexanet alfa influences overall market dynamics.
• Growth opportunities include off-label uses and geographic expansion.

FAQs

Q1: What factors have limited idarucizumab’s market penetration outside North America?
A1: Reimbursement challenges, regulatory delays, and physician familiarity impact adoption in certain regions.

Q2: How does idarucizumab compare cost-wise to other reversal agents?
A2: It has high manufacturing costs but maintains gross margins over 80%. Pricing strategies are influenced by reimbursement negotiations.

Q3: Are there new formulations or delivery methods in development?
A3: Currently, no significant new formulations are in late-stage development; focus remains on label expansion and off-label uses.

Q4: What are the main competitors for idarucizumab?
A4: No direct competitors for dabigatran reversal; however, andexanet alfa competes in the factor Xa inhibitor reversal space.

Q5: What regulatory agencies are most influential for future approvals?
A5: The FDA, EMA, and other jurisdictional agencies like PMDA (Japan) are pivotal for new indications and market expansion.

---

References

[1] U.S. Food and Drug Administration. (2015). FDA approves Praxbind to reverse anticoagulant dabigatran.
[2] European Medicines Agency. (2015). EMA approves Praxbind for dabigatran reversal.
[3] IQVIA. (2022). Global Biotech Dashboard.
[4] MarketWatch. (2022). Biologics market analysis and forecasts.